---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-055682"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T13:58:54.318078+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arvinas reports preclinical data showing ARV-393 + glofitamab combo yields up to 91% TGI in lymphoma model

## Summary
- ARV-393 (3 mg/kg) + glofitamab achieved 81% TGI (concomitant) and 91% TGI (sequential) vs 38% and 36% single-agent.
- At 6 mg/kg ARV-393 combo, tumor regressions in 10/10 mice (concomitant) and 7/8 (sequential) vs 5/11 and 0/11 alone.
- RNA-seq showed ARV-393 upregulated CD20, interferon signaling, antigen presentation; downregulated proliferation genes.
- Phase 1 trial of ARV-393 in relapsed/refractory non-Hodgkin lymphoma ongoing; clinical data due at medical congress in 2026.
- Company plans to add glofitamab combination cohort in DLBCL to ongoing Phase 1 trial in 2026.

## SEC filing metadata
- accession: 0001628280-25-055682
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000162828025055682/0001628280-25-055682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000162828025055682/arvn-20251206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-055682
- JSON: https://secwatch.observer/filing/0001628280-25-055682.json
- Plain text: https://secwatch.observer/filing/0001628280-25-055682.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.